Research information only, not medical advice. Research peptide, not approved for human use anywhere. Up for an FDA advisory committee vote on July 24, 2026 (evaluated indication: Opioid withdrawal, chronic insomnia, narcolepsy). Removed from the FDA 'do not compound' list in April 2026 but not yet compoundable.
DSIP at a glance
As of June 2026 the human evidence is limited; most data is preclinical. See the indexed studies below, graded by evidence level.
The peptides on the agenda are covered in the July 2026 FDA peptide meeting .
Evidence profile
58 studies- Human trial 1 · 2%
- Review 5 · 9%
- Animal 20 · 34%
- In-vitro 12 · 21%
- Unknown 20 · 34%
The longer the green, the stronger the human evidence. For most research peptides the bar is dominated by animal and in-vitro work, which is a signal to read every claim carefully.
Regulatory status
- 2026-04-22 US-FDA
Removed from the FDA 503A 'do not compound' Category 2 (nominations withdrawn) — still not eligible for compounding. source
- 2026-07-24 US-FDA · upcoming
FDA Pharmacy Compounding Advisory Committee vote (evaluated indication: Opioid withdrawal, chronic insomnia, narcolepsy); docket FDA-2025-N-6895. source
Indexed research
Sorted by evidence level, strongest first.
- Human trial 2014[Using deltalicin for the treatment of patients with diabetic retinopathy]
- Review 2026Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
- Review 2025Transforming Digital Signal and Image Processing Education: An AI-Driven Approach to Pedagogical Advancements
This review discusses the integration of AI tools and active learning methods in Digital Signal and Image Processing education.
- Review 2024The Search For And Evaluation Of Sleep-Inducing Substances
This book chapter reviews historical and current research on endogenous sleep-inducing substances, noting that their mechanisms remain unclear.
- Review 2024Muramyl Peptides And Interleukin-1 As Promoters Of Slow Wave Sleep
This book chapter reviews historical and experimental evidence for sleep-promoting substances, focusing on muramyl peptides and interleukin-1.
- Review 2026PEPTIDE BIOREGULATORS, AGING AND HUMAN LONGEVITY: EPITHALON, THYMALIN, THYMOGEN, DSIP, VILON AND VESUGEN IN CIRCADIAN BIOLOGY, TELOMERASE REGULATION AND INFLAMMAGING
This integrative review analyzes the biomolecular mechanisms of peptide bioregulators Epithalon, Thymalin, Thymogen, DSIP, Vilon, and Vesugen in aging and longevity, highlighting experimental evidence but noting insufficient robust clinical trials for translational efficacy.
- Animal 2024Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models
- Animal 2021Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke
- Animal 2021DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl/6 and Reduces Myocardial Infarction in SD Rats When Administered during Reperfusion
- Animal 2018Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude
+ 48 more studies indexed for DSIP.
Frequently asked questions
- Is DSIP approved for human use?
- Research peptide, not approved for human use anywhere. Up for an FDA advisory committee vote on July 24, 2026 (evaluated indication: Opioid withdrawal, chronic insomnia, narcolepsy). Removed from the FDA 'do not compound' list in April 2026 but not yet compoundable.
- What does the research on DSIP show?
- As of June 2026 the human evidence is limited; most data is preclinical. See the indexed studies below, graded by evidence level.